Get the Daily Brief
Latest Biotech News
Recursion hands Roche a microglia map — $30M milestone for AI phenomics
Recursion delivered a genome‑scale microglia phenomap to Roche/Genentech as part of their multi‑year AI discovery collaboration, triggering a $30 million milestone payment. The dataset—millions of...
Tubulis upsizes Series C to $401M — doubling down on ADC platforms
Munich‑based Tubulis expanded its Series C financing to $401 million to accelerate development of its next‑generation antibody‑drug conjugate (ADC) platform. The company said the fresh capital...
Lilly doubles down: buys Adverum for ocular gene therapy and builds AI supercomputer with Nvidia
Eli Lilly agreed to acquire Adverum in a deal focused on ixoberogene soroparvovec (ixo‑vec), a Phase III one‑time gene therapy for wet age‑related macular degeneration, and separately announced a...
GLP‑1 commercialization shift: Lilly builds oral factory while DTC drives Zepbound scripts
Eli Lilly budgeted $1.2 billion for a Puerto Rico plant dedicated to producing an oral GLP‑1 candidate, part of capacity expansion to meet soaring demand for incretin‑class drugs. Separately,...
10x Genomics launches next‑gen Chromium Flex — 384‑plex single‑cell at scale
10x Genomics unveiled the next‑generation Chromium Flex assay, enabling automation‑compatible plate‑based multiplexing for up to 384 samples and claimed throughput of up to 100 million cells per...
FDA moves to fast‑track biosimilars — clinical bar lowered
The U.S. Food and Drug Administration issued new draft guidance to speed approval of biosimilars by reducing or removing requirements for comparative Phase III efficacy studies. Agency leaders...
FDA places clinical hold on Intellia trials — gene‑editing safety alarms
The FDA placed a clinical hold on Intellia Therapeutics’ two late‑stage trials of its CRISPR gene‑editing candidate following a serious liver injury reported in a participant, prompting a trading...
Thermo Fisher to buy Clario — $8.9B cash for trial data muscle
Thermo Fisher Scientific agreed to acquire Clario, a clinical trial data solutions firm, in a deal valued at up to $9.4 billion. The transaction — disclosed with an $8.9 billion upfront cash...
Roche licenses Qyuns bispecific — $1.07B respiratory bet
Roche secured global rights to Qyuns Therapeutics’ long‑acting bispecific antibody QX‑031N in a deal that starts with a $75 million upfront payment and could top $1.07 billion in development and...
BridgeBio posts Phase III wins — rare disease filings ahead
BridgeBio Pharma reported positive late‑stage data for encaleret in an autosomal dominant form of hypoparathyroidism and signaled plans to pursue regulatory filings, marking back‑to‑back Phase III...
Lilly doubles down on scale and AI — $1.2B plant and supercomputer
Eli Lilly disclosed a two‑pronged expansion strategy: a $1.2 billion plant in Puerto Rico to produce oral GLP‑1 candidate orforglipron and an alliance with Nvidia to build a massive AI...
Lilly buys Adverum — single‑dose ocular gene therapy in hand
Eli Lilly agreed to acquire Adverum to advance ixoberogene soroparvovec (ixo‑vec), a one‑time AAV‑based gene therapy in Phase III for wet age‑related macular degeneration (wAMD). Lilly said it...
Kyverna CAR‑T posts robust gMG signals — phase III next
Kyverna Therapeutics released interim Phase II results showing strong efficacy for KYV‑101, an autologous CD19 CAR‑T with CD28 costimulation, in generalized myasthenia gravis (gMG). The company...
10x Genomics launches next‑gen Flex — single‑cell at scale
10x Genomics rolled out the next generation of its Chromium Flex assay, enabling automation‑compatible, plate‑based multiplexing for high‑throughput single‑cell studies. The company said the new...
Stat profile: Moderna unravels — cash, contracts and strategy under pressure
A STAT feature chronicles Moderna’s post‑pandemic retrenchment, detailing slumping Covid‑vaccine revenues, government contract cancellations, layoffs and a sharp market‑value decline from 2021...
FDA moves to speed biosimilars: draft would drop clinical comparators
The U.S. Food and Drug Administration unveiled a draft framework proposing to eliminate routine Phase III comparative efficacy trials for biosimilar approvals. The agency, led by Commissioner...
Thermo Fisher to buy Clario — up to $9.4 billion for trial data assets
Thermo Fisher Scientific agreed to acquire Clario, a clinical trial software and data solutions company, in a deal worth about $8.9–$9.4 billion in cash. The transaction brings trial management,...
Roche inks China deal for bispecific respiratory antibody — $75M up front
Roche secured global rights to Qyuns Therapeutics’ bispecific antibody QX-031N in a licensing and collaboration that starts with a $75 million upfront payment and reaches up to roughly $1.07...
FDA halts Intellia gene-editing trials after patient liver injury
The U.S. Food and Drug Administration placed a clinical hold on two late‑stage Intellia Therapeutics trials testing a CRISPR-based in vivo gene-editing therapy after a serious liver injury in a...
BridgeBio posts two Phase III wins — rare disease results move toward filings
BridgeBio announced positive Phase III results for two rare‑disease programs, delivering a double win for the company. Encaleret met primary and key secondary endpoints in autosomal dominant...